Our Diagnostic – Gastriome
Between 25 million and 45 million people in the U.S. suffer from Irritable Bowel Syndrome (IBS) (aboutibs.org). Some of those individuals are ultimately diagnosed with Ulcerative Colitis (UC) or Crohn’s Disease (CD). Some of the symptoms of IBS may be similar to or raise suspicion of IBD.
Current methods for the initial clinical diagnosis of UC and CD remain challenging. Current tests for IBD rely mostly on invasive procedures (e.g., colonoscopies, endoscopies, and biopsies).
The development of a stool-based diagnostic test for IBD will provide a non-invasive, cost effective alternative.
Biomecite Diagnostics has developed a software based microbiome diagnostic platform
Microbiome – altered
by diseases in the body
NextGen DNA – cost
Patent pending algorithms
identify disease states
based on variations in the
IBS and IBD IMPACTS MILLIONS of people worldwide
Irritable Bowel Syndrome (IBS) affects
between 25 and 45 million people
in the United States (aboutibs.org)
IBD affects about 1.6 million people
in the United States and about 70,000
new cases are diagnosed each year. (CCFA)
Five million people worldwide
suffer from IBD
How It Works
Proof of Concept Study
Biomecite Diagnostics is currently conducting a proof of concept study in 90 patients, utilizing funding from TEDCO. The study is designed to demonstrate the accuracy of a new diagnostic technology to allow physicians to diagnose Inflammatory Bowel Disease (IBD). The project is being managed by CSSi LifeSciences™ with a clinical site in Annapolis, Maryland and will be completed in early 2016.